About Us
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides).
Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome’s Mimicry drug discovery platform uses best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million full-length gut microbiome proteins. This platform is highly productive and has already generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.
Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones or cytokines. The Company is presently advancing its proprietary OncoMimics™ pipeline of distinct drug candidates – EO2401 in glioblastoma and adrenal tumors, EO2463 in indolent non-Hodgkin lymphomas, and EO4010 for third-line colorectal cancer.
Key Figures
20+ million
full length and functional proteins from the gut microbiome
€116 million
financing raised
21 patent families filed
3 in-licensed patent families,
9 Trademarks filed
70
employees
Our leadership team
Board of Directors
Scientific Advisory Board
Partners
Enterome signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb in March 2021 to support EO2401, an OncoMimicsTM vaccine in clinical development.
As a result of this agreement, BMS has committed to the supply, free of charge, of nivolumab for patients participating in the combined therapy clinical trials ROSALIE (EOGBM1-18) and SPENCER (EOADR1-19).
In July 2022 Enterome signed a major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease.
Under the terms of the agreement, Enterome has received a €40 million upfront payment from Nestlé Health Science, in cash and in equity, and is also eligible to receive clinical and sales milestones payments for each licensed therapeutic candidate, plus royalties on net sales. Enterome will be responsible for leading drug discovery activities and bear related costs up to investigational new drug (IND) application.
Investors
Enterome was established in 2012 and has raised €135 million in financing rounds with private equity funds, strategic investors and in loans.